Pharming « Terug naar discussie overzicht

Pharming het aandeel van 2017

50.750 Posts, Pagina: « 1 2 3 4 5 6 ... 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 ... 2534 2535 2536 2537 2538 » | Laatste

Omlaag ↓

[verwijderd] 21 augustus 2017 15:16

TIDMSHP

Shire plc Director and Senior Management Changes

August 21, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) ("Shire" or the
"Company"), announces changes to its Executive Committee, as it
progresses its strategy to sharpen its focus as a leader in rare
diseases.

Jeff Poulton, Chief Financial Officer, will be leaving Shire at the end
of the year to serve as CFO at Indigo Ag, Inc., a start-up company based
in Boston that uses the plant microbiome to improve the productivity and
sustainability of agriculture. The Board will commence a formal search
for a successor and Jeff will continue to serve in his current role as
this search progresses. During this transition period, Jeff will remain
on the Executive Committee and on the Board of Directors of Shire plc.
Jeff will also continue to support the Company's on-going strategic
review of its business.

Dr. Flemming Ornskov, MD, MPH, Chief Executive Officer, said: "It is
with regret that we announce Jeff's upcoming departure. Having held
numerous roles within the Company, Jeff has demonstrated steadfast
commitment to Shire through a very intense period of activity and has
made significant contributions to our organization. Jeff will continue
to lead the Shire Finance team through the Q3 reporting period and to
the end of the year, and will play an active role in the search for his
successor. On behalf of all Shire employees, we are grateful to Jeff
for his dedication and leadership and wish him the very best in his
future endeavours."

Jeff Poulton, Chief Financial Officer, said: "It has been a privilege to
work for Shire and to have played a part in the exceptional growth story
of such an inspirational company. It has been a difficult decision, but
in departing Shire, I wanted to join a smaller organization where I can
play a role in building a new company. As Shire finalizes the
integration of Baxalta and focusses on paying down debt, this also
presents a perfect time for me to begin this transition. I know I leave
Shire well positioned to pursue its strategy and deliver value for
shareholders, supported by a strong Finance team."

Susan Kilsby, Chairman of the Board, said: "On behalf of the Board of
Directors, I want to thank Jeff for his long tenure and unwavering
dedication to Shire and our patients. While we will miss Jeff's positive
spirit and professionalism, we understand his decision to start a new
career. During Jeff's time at Shire he has travelled the globe,
transformed the Finance department, and led the continued successful
integration of Baxalta and many other acquisitions. We fully appreciate
his contributions that have helped to make Shire a great organization."

This notification is to satisfy the Company's obligations under LR
9.6.11R of the UK Listing Rules.

The Company also announces that Joanne Cordeiro has been appointed Chief
Human Resources Officer and a member of the Executive Committee,
effective immediately. Joanne takes over the role held by Ginger
Gregory. Joanne joined Shire in March 2011 and has been serving as
Interim Head of Human Resources since March 2017. Before joining Shire,
Joanne served in various Human Resources management and executive search
roles at Teradyne Inc., Covansys Corporation (now a DXC Technology
Company), Avid Technology, Inc., and Sybase Inc. (now an SAP company).

In reference to Joanne's appointment, Dr. Ornskov said: "I have worked
closely with Joanne over the past several years as we have transformed
Shire into the global leader in the treatment of rare diseases. Joanne's
dedication, skill, and expertise have been an invaluable resource in the
successful integration of Baxalta into the Shire business. She is a
trusted partner to the entire management team and a passionate supporter
of our in-house talent and leadership development programs, which are
crucial to our business."

Joanne Cordeiro, Chief Human Resources Officer, said: "It is an honor to
accept this appointment and I look forward to the opportunity to
continue building on the expertise and passion of my colleagues at Shire,
attracting top talent to our organization, and working with the rest of
the Executive Committee, all of whom are dedicated to improving the
lives of the patients we serve."

For further information please contact:

Investor Relations
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com +1 617 949 9083

For information regarding Indigo Ag, Inc., please contact:

Lauren Ashbrook lashbrook@indigoag.com + 1 617 909-9390

NOTES TO EDITORS

Stephen Williams, Deputy Company Secretary, is responsible for arranging
the release of this announcement.

Inside Information

This announcement contains inside information.

Remuneration

Jeff Poulton will continue to be paid in line with his current
remuneration arrangements until his date of departure. Details of the
remuneration arrangements relating to Mr. Poulton's departure will be
disclosed in due course.

About Shire

Shire is the leading global biotechnology company focused on serving
people with rare diseases. We strive to develop best-in-class products,
many of which are available in more than 100 countries, across core
therapeutic areas including Hematology, Immunology, Neuroscience,
Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal
Medicine / Endocrine and Hereditary Angioedema; and a growing franchise
in Oncology.

Our employees come to work every day with a shared mission: to develop
and deliver breakthrough therapies for the hundreds of millions of
people in the world affected by rare diseases and other high-need
conditions, and who lack effective therapies to live their lives to the
fullest.

www.shire.com

This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.

Source: Shire plc via Globenewswire
(END) Dow Jones Newswires
August 21, 2017 09:15 ET (13:15 GMT)
© 2017 Dow Jones & Company, Inc.

AAND SHIRE @ GBP 0.05
JE00B2QKY057
AAND SHIRE PLC ADR
US82481R1068

antop 21 augustus 2017 15:17

0,459 inzicht gaat lekker

Cor S 21 augustus 2017 15:20

quote:
Gr€€d1 schreef op 21 augustus 2017 14:59:
[...]Als jij nog moet afronden, wel :P

Gr€€d1, haha ik hou van afronden - ga nu eerst voor de 0,46!

antop 21 augustus 2017 15:21

sluiten 0,467

[verwijderd] 21 augustus 2017 15:21

quote:
hangklok schreef op 21 augustus 2017 13:57:
Ik heb vorige week 40k verkocht voor 0,432 zit er nu nog met 40 k in ik verwacht dat de koers de 0,41 deze week nog wel en keer opzoekt. Er zijn nog heel wat warrants in de koker.

hoop dat je een voda buik hebt want begin maar vast te schrijven !

Ruud..

[verwijderd] 21 augustus 2017 15:22

quote:
hangklok schreef op 21 augustus 2017 15:04:
[...]Ja dat ik vorige week 40k te vroeg heb verkocht Dit kost me 1000 piek

Dus 2000.

Ruud..

hangklok 21 augustus 2017 15:25

quote:
Declan schreef op 21 augustus 2017 15:22:
[...]

Dus 2000.

Ruud..

40k verkocht op 0,432 vorige week en 40 k gehouden 40k X 0,025= € 1000, -- volgens mij en geen 2000, --

antop 21 augustus 2017 15:25

wie pakt die 600.000 stukkies ff weg uit de laat..stomen we door

antop 21 augustus 2017 15:25

Hoogste 0,459 15:24:32

Beuk 21 augustus 2017 15:28

En dit bij laag volume.
?????

antop 21 augustus 2017 15:28

0,46

[verwijderd] 21 augustus 2017 15:29

quote:
hangklok schreef op 21 augustus 2017 15:25:
[...]40k verkocht op 0,432 vorige week en 40 k gehouden 40k X 0,025= € 1000, -- volgens mij en geen 2000, --

Als je over piek begint zijn dat er 2000 klokkie
;-)

Ruud..

antop 21 augustus 2017 15:30

15:27:29 0,459 50.000
15:27:29 0,459 30.000

volumes gaan omhoog

[verwijderd] 21 augustus 2017 15:31

inderdaad een laag volume!!

antop 21 augustus 2017 15:32

krijgen een frezen up let maar op

EFBO 21 augustus 2017 15:32

Weet Shire dat Pharming bestaat ?

Beuk 21 augustus 2017 15:34

Er moet iets aan de hand zijn

[verwijderd] 21 augustus 2017 15:35

Ik denk dat Sijmen met een opwaartse bijstelling gaat komen wat betreft kw 3 en de rest van het jaar
Zowel omzet als winst

Steenbok1972 21 augustus 2017 15:36

Er speelt iets....Maar wat

antop 21 augustus 2017 15:37

Alle seinen staan op groen...uitbraak richting 0,50 en hoger is in aantocht..je kan ze maar beter hebben en vasthouden!

50.750 Posts, Pagina: « 1 2 3 4 5 6 ... 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 ... 2534 2535 2536 2537 2538 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Direct naar Forum

Detail

Vertraagd	21 feb 2025 17:35
Koers	0,873
Verschil	-0,002 (-0,29%)
Hoog	0,884
Laag	0,864
Volume	2.251.436
Volume gemiddeld	5.503.784
Volume gisteren	3.202.265

Pharming nieuws meer

20 feb	Pharming heeft bijna 93% van Abliva i...	1
07 feb	Pharming verklaart bod op Abliva onvo...
21 jan	Pharming stemt over nieuwe CEO
21 jan	Pharming presenteert nieuwe CEO
16 jan	Fundlogic verkoopt bijna geheel belan...	4
15 jan	Fundlogic flink groter in Pharming	1
07 jan	DWS meldt groter belang in Pharming
31 dec	Morgan Stanley groter in Pharming
23 dec	CEO: Pharming koopt met KL1333 van Ab...
19 dec	RBC verhoogt koersdoel Pharming fors